Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin’s Lymphoma
Press release content from PR Newswire. The AP news staff was not involved in its creation. https://apnews.com/press-release/PR%2520Newswire/5d3644900c8888618388e38979faf1f9Click to copy SHANGHAI and PHILADELPHIA, April 14, 2020 /PRNewswire/ — Antengene announced today that it has dosed the first patient in Taiwan, China in its phase 1 open-label clinical trial of ATG-019 (KPT-9274), a dual inhibitor of both PAK4 and NAMPT. This trial...